146 related articles for article (PubMed ID: 10492142)
1. Use of FDP and F1P aldolase to detect tumorous and nontumorous tissue damage by ethanol injection of hepatocellular carcinoma.
Khan KN; Nakata K; Nakao K; Kato Y; Eguchi K
Dig Dis Sci; 1999 Aug; 44(8):1610-8. PubMed ID: 10492142
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of nontumorous tissue damage by transcatheter arterial embolization for hepatocellular carcinoma.
Khan KN; Nakata K; Kusumoto Y; Shima M; Ishii N; Koji T; Nagataki S
Cancer Res; 1991 Oct; 51(20):5667-71. PubMed ID: 1717151
[TBL] [Abstract][Full Text] [Related]
3. Use of fructose 1,6-diphosphate aldolase to detect tumour necrosis after transcatheter arterial embolization of hepatocellular carcinoma.
Khan KN; Nakata K; Kusumoto Y; Nakao K; Kato Y; Nagataki S
J Gastroenterol Hepatol; 1998 Feb; 13(2):192-6. PubMed ID: 10221823
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.
Pompili M; Rapaccini GL; Covino M; Pignataro G; Caturelli E; Siena DA; Villani MR; Cedrone A; Gasbarrini G
Cancer; 2001 Jul; 92(1):126-35. PubMed ID: 11443618
[TBL] [Abstract][Full Text] [Related]
5. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma.
Dettmer A; Kirchhoff TD; Gebel M; Zender L; Malek NP; Panning B; Chavan A; Rosenthal H; Kubicka S; Krusche S; Merkesdal S; Galanski M; Manns MP; Bleck JS
World J Gastroenterol; 2006 Jun; 12(23):3707-15. PubMed ID: 16773687
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection.
Pompili M; Rapaccini GL; de Luca F; Caturelli E; Astone A; Siena DA; Villani MR; Grattagliano A; Cedrone A; Gasbarrini G
Cancer; 1997 Apr; 79(8):1501-8. PubMed ID: 9118030
[TBL] [Abstract][Full Text] [Related]
7. Decreased serum aldolase B levels in patients with malignant tumors.
Asaka M; Kimura T; Nishikawa S; Miyazuki T; Alpert E
Cancer; 1988 Dec; 62(12):2554-7. PubMed ID: 3191454
[TBL] [Abstract][Full Text] [Related]
8. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection.
Khan KN; Yatsuhashi H; Yamasaki K; Yamasaki M; Inoue O; Koga M; Yano M
J Hepatol; 2000 Feb; 32(2):269-78. PubMed ID: 10707867
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous ethanol injection, radiofrequency and their combination in treatment of hepatocellular carcinoma.
Luo BM; Wen YL; Yang HY; Zhi H; Xiao XY; Ou B; Pan JS; Ma JH
World J Gastroenterol; 2005 Oct; 11(40):6277-80. PubMed ID: 16419155
[TBL] [Abstract][Full Text] [Related]
10. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma presenting as intracranial metastasis.
Lee JP; Lee ST
Surg Neurol; 1988 Oct; 30(4):316-20. PubMed ID: 2459797
[TBL] [Abstract][Full Text] [Related]
12. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
Giannini EG; Sammito G; Farinati F; Ciccarese F; Pecorelli A; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Gasbarrini A; Sacco R; Foschi FG; Missale G; Morisco F; Svegliati Baroni G; Virdone R; Trevisani F;
Cancer; 2014 Jul; 120(14):2150-7. PubMed ID: 24723129
[TBL] [Abstract][Full Text] [Related]
13. Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase.
Kim YI; Kim HS; Park JW
PLoS One; 2016; 11(6):e0157299. PubMed ID: 27304617
[TBL] [Abstract][Full Text] [Related]
14. Multiple non-tumorous arterioportal shunts due to chronic liver disease mimicking hepatocellular carcinoma: outcomes and the associated elevation of alpha-fetoprotein.
Takayasu K; Muramatsu Y; Mizuguchi Y; Moriyama N; Okusaka T
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):288-94. PubMed ID: 16460488
[TBL] [Abstract][Full Text] [Related]
15. Value of serum alpha-fetoprotein and ferritin in the diagnosis of hepatocellular carcinoma.
Tatsuta M; Yamamura H; Iishi H; Kasugai H; Okuda S
Oncology; 1986; 43(5):306-10. PubMed ID: 2429242
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of percutaneous ethanol injection on small hepatocellular carcinoma: evaluation with CT.
Ebara M; Kita K; Sugiura N; Yoshikawa M; Fukuda H; Ohto M; Kondo F; Kondo Y
Radiology; 1995 May; 195(2):371-7. PubMed ID: 7536946
[TBL] [Abstract][Full Text] [Related]
17. [The distribution of the aldolase isoenzymes in various human tissues and the anomaly in cancerous tissues -especially in gastric cancer- (author's transl)].
Saito H
Hokkaido Igaku Zasshi; 1975 Nov; 50(6):540-8. PubMed ID: 1240853
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients.
Nomura F; Ohnishi K; Tanabe Y
Cancer; 1989 Oct; 64(8):1700-7. PubMed ID: 2477133
[TBL] [Abstract][Full Text] [Related]
19. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients.
Lencioni R; Bartolozzi C; Caramella D; Paolicchi A; Carrai M; Maltinti G; Capria A; Tafi A; Conte PF; Bevilacqua G
Cancer; 1995 Nov; 76(10):1737-46. PubMed ID: 8625042
[TBL] [Abstract][Full Text] [Related]
20. Aldolase A isoenzyme levels in serum and tissues of patients with liver diseases.
Asaka M; Nagase K; Miyazaki T; Alpert E
Gastroenterology; 1983 Jan; 84(1):155-60. PubMed ID: 6183164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
